The in vivo efficacies of pefloxacin, a new fluoroquinolone, and amikacin-ceftazidime were compared in 50 rabbits with experimental aortic endocarditis caused by Pseudomonas aeruginosa. Animals were randomly chosen to receive 4 or 10 days of no therapy (controls) Pefloxacin and both amikacin regimens significantly reduced vegetation bacterial densities compared with controls at days 4 and 10 of treatment (P < 0.0005). By day 10 of therapy, between 33 and 40% of vegetations from amikacin-ceftazidime recipients contained ceftazidime-resistant bacteria (MICs, >25 ,ug/ml); nitrocefin agar overlay confirmed that these ceftazidime-resistant variants were constitutive overproducers of 0-lactamase. At therapy days 4 and 10, -30% of vegetations sampled from pefloxacin recipients contained bacteria for which pefloxacin MICs were four-to eightfold higher than the MIC for the parental strain used to initially induce endocarditis (MIC, 0.19 ,ig/ml). These variants also exhibited increases in ciprofloxacin and ticarcillin MICs, as well as pleotropic resistance to chloramphenicol (but not to amikacin, ceftazidime, or tetracycline). Amikacin-ceftazidime, as well as pefloxacin, was effective in this model of aortic pseudomonal endocarditis. However, in vivo development of ceftazidime resistance and step-ups in pefloxacin MICs among intravegetation isolates were associated with inability to completely eradicate P. aeruginosa from aortic vegetations.
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Infective endocarditis caused by Pseudomonas aeruginosa has been prevalent among parenteral drug abusers in major metropolitan centers (e.g., Detroit and Chicago [25] ). Although clinical outcomes have improved for patients with right-sided valvular infection, the medical cure rates for those with aortic or mitral valve involvement continue to be disappointing (25) . In vivo development of antibiotic resistances to the P-lactams and aminoglycosides commonly used to treat these infections has been an important factor in the suboptimal outcome of left-sided pseudomonal endocarditis in both humans and experimental models (6, 19, 23, 25) . The new fluoroquinolones, possessing potent in vitro bactericidal activity against P. aeruginosa strains (2, 9, 13), are important potential agents for evaluation in invasive pseudomonal infections such as endocarditis.
The current study was designed to (i) evaluate pefloxacin, a new quinolone with a prolonged half-life, in experimental aortic valve P. aeruginosa endocarditis; (ii) compare this regimen to high-dose aminoglycoside-p-lactam (amikacinceftazidime) therapy, which exhibits in vitro bactericidal synergy against the infecting strain; and (iii) examine these two therapeutic regimens for in vivo development of antimicrobial resistances.
(Part of this research was presented at the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, N.Y., 4 to 7 October 1987.)
MATERIALS AND METHODS Organism. The P. aeruginosa strain used to infect catheterized rabbits in this study (PA-96) was a clinical isolate that has been used in our earlier studies of experimental endo-* Corresponding author.
carditis (3) (4) (5) (6) (7) 11) . Its identification, serotyping, and rabbit serum resistance have been previously described (11) . Ceftazidime MICs and MBCs for the organism both are 8 ,g/ml and those of amikacin are 2 ,ug/ml, respectively, as determined by the broth macrodilution technique at -105 cells per inoculum (6) ; these values are 32 and 8 pug/ml when determined at -107 cells per inoculum (6) . The pefloxacin MIC and MBC for this strain are 0.19 and 0.76 ,g/ml, respectively, at both 105 and 107 cells per inoculum.
In vitro bactericidal interactions. We have previously shown that amikacin-ceftazidime synergistically kills the infecting pseudomonal strain in vitro at -105 cells per inoculum but exerts an indifferent effect when the challenge inoculum contains i107 cells (6) . The time-kill kinetics of pefloxacin for PA-96 were determined at challenge inocula of _105 and 107 logarithmic-phase cells in Mueller-Hinton (MH) broth. The final pefloxacin concentrations tested were 5, 10, and 15 jig/ml to encompass achievable levels in serum for this agent in humans after parenteral dosages (14) . Subculture times were 0, 4, and 24 h, after which curves were constructed comparing surviving log1o CFU/ml versus incubation times.
Induction ). These regimens have consistently produced amikacin and ceftazidime peak levels in serum -8 to 10 times above the MBC for the infecting organism in pilot studies in our laboratory. Therapy was begun 24 h postinoculation. We did not include ceftazidime or amikacin monotherapy regimens, since such regimens have been associated with poor bacteriologic efficacy in this model (6) .
Intravegetation bacterial densities. Animals were sacrificed by rapid intravenous injection of 150 mg of sodium pentobarbital after either day 4 or 10 of therapy. At sacrifice, aortic valve vegetations were excised, weighed, homogenized in MH broth, and quantitatively subcultured as previously described (6) . No attempt was made to inactivate antibiotics in the vegetation homogenates, since sacrifices were performed at least 18 h after the last drug dose (26) ; also, serial dilutions of the homogenate during the subculture procedure tend to minimize antibiotic carry-over. Animals that had been dead longer than 6 h before postmortem examination were excluded from bacteriologic evaluation (26) . In calculating mean intravegetation bacterial densities, culture-negative vegetations were considered to contain <2 log1o CFU/g on the basis of the average vegetation weight (0.01 g [8] ). Portions of each homogenate were subcultured in parallel onto MH agar containing either ceftazidime or amikacin (25 pg/ml) or pefloxacin (2 ,ug/ml), depending on the therapeutic regimen, to detect in vivo development of resistance. These drug concentrations were chosen to approximate the respective breakpoints for delineating resistance (21, 29) . To define the relative proportions of antibiotic-resistant and antibiotic-susceptible isolates within individual vegetations, a resistance ratio was calculated (10).
This ratio is defined as the log1o of the ratio of the number of resistant organisms to the total number of organisms within a vegetation. To delineate in vivo selection of ceftazidimeresistant variants stably derepressed for ,-lactamase overproduction, colonies on ceftazidime-containing plates (as well as the parallel-cultured colonies on antibiotic-free MH agar) were overlaid with nitrocefin-containing MH agar (50 ,ug/ml), as previously described (15) . Vegetation homogenate subculture plates not exhibiting growth on ceftazidimecontaining media were also overlaid with nitrocefin as a control. A pink staining of the agar surrounding the colonies within 3 min of overlay was considered a positive overlay for detection of P-lactamase overproduction and has been correlated with stable derepression of chromosomal 1-lactamase of Enterobacter cloacae (15) .
To determine possible quinolone cross resistance and pleotropic resistance among intravegetation isolates growing on pefloxacin-containing agar, selected organisms were grown in antibiotic-free MH broth to logarithmic phase, and the MICs for the organisms were retested against a panel of antibiotics by the broth macrodilution technique (inoculum, _105 CFU/ml [21] ); the parental strain was included in this testing as a control. The following agents were used: pefloxacin, ciprofloxacin, ceftazidime, amikacin, chloramphenicol, ticarcillin, and tetracycline.
Antibiotic concentrations in serum. On day 2 of antibiotic administration, blood was drawn 1 h after and just before amikacin or ceftazidime administration or 2 h after and just before pefloxacin administration to measure near peak and trough serum concentrations for the respective agents. Pefloxacin levels were determined by bioassay by using the agar-well diffusion technique with Escherichia coli ATCC 10536 as the assay organism; the sensitivity of the assay was 0.125 ,g/ml. Amikacin levels were determined by high-pressure liquid chromatography, with an assay sensitivity of 0.25 ,ug/ml. Ceftazidime levels were determined by agar-well diffusion bioassay with an amikacin-resistant E. coli strain (kindly provided by Janet Hindler, University of California, Los Angeles); the assay sensitivity was 0.125 ,ug/ml.
Statistical evaluation. The chi-square test with Yates correction was used for comparing proportional data, whereas the analysis of variance was used for comparing differences between mean log1o CFU per gram of vegetation. P values less than or equal to 0.05 were considered to be significant.
RESULTS
Time-kill curves. At 105 cells per inoculum, pefloxacin at 10 and 15 ,ug/ml (but not at 5 1xg/ml) rendered the initial inoculum culture negative at 24 h of incubation (Fig. 1) . At 107 cells per inoculum, the three pefloxacin concentrations caused a decrease in surviving CFUs per milliliter of -2.5 to 4.2 log1o at 24 h of incubation (Fig. 2) .
Animal experiments. (i) Intravegetation bacterial densities. All three antibiotic regimens significantly lowered mean bacterial densities within vegetations, compared with untreated controls at both days 4 and 10 of therapy (P < 0.0005); however, only the higher amikacin dose regimen (80 mg/kg per day) resulted in a continued significant reduction in bacterial densities when mean values for day 4 were compared with those of day 10 (P < 0.005) ( Table 1) .
(ii) In vivo development of resistance. At day 4 of therapy, no vegetations from animals in either amikacin treatment group contained amikacin-or ceftazidime-resistant variants; however, 27% of vegetations from pefloxacin-treated animals contained variants which grew on pefloxacin agar (2 ,ug/ml) ( Table 2 ). At day 10 of treatment, no amikacinresistant variants were noted in vegetation cultures of animals receiving this agent at either dosage regimen. In contrast to findings at day 4 of therapy, between 33 and 40% of vegetations obtained from animals receiving 10 days of amikacin-ceftazidime treatment contained ceftazidime-resistant variants (MIC, >25 ,ug/ml). After 10 days of pefloxacin treatment, 31% of vegetations contained pseudomonal colonies which grew in the presence of pefloxacin (2 ,ug/ml). For the ceftazidime-resistant variants, the resistance ratios ranged from -0.13 to -2.36 (mean ± standard error of the mean [SEM], -1.07 ± 0.71). Similarly, the resistance ratios for vegetations yielding variants capable of growth on pefloxacin-containing media ranged from -1.19 to -2.18 (mean ± SEM, -1.68 ± 0.17]).
(iii) In vitro analyses of antibiotic-resistant variants from cardiac vegetations. All 15 nitrocefin agar overlay tests performed upon variant pseudomonal colonies growing on both ceftazidime-containing and antibiotic-free agar were positive for ,-lactamase overproduction. Since ceftazidime is a poor inducer of chromosomal P-lactamase, the positive nitrocefin agar overlay suggests that there is in vivo selection of stably derepressed mutants (15) . Colonies isolated from vegetations exhibiting no growth on ceftazidime-containing agar were uniformly negative in the nitrocefin agar overlay assay. Table 3 shows cross-and pleotropic resistance studies of selected pseudomonal variants from vegetation homogenates yielding growth on pefloxacin-containing plates. There was a four-to eightfold step-up in both pefloxacin and ciprofloxacin MICs for the variants, compared with the parental strain (PA-96); however, these variants would still be considered susceptible to these agents based on breakpoint criteria (susceptible is <2 jig/ml [21, 29] ). There was no cross resistance observed to the 13-lactam (ceftazidime) and aminoglycoside (amikacin) agents used in the study; however, the ticarcillin MICs were increased in two of the three 9. variants by two-to fourfold, compared with the parental strain (32 to 64 jig/ml versus 16 ,ug/ml, respectively). Interestingly, these variants developed cross resistance to chloramphenicol, but not to tetracycline, with increases in MICs of 160-to 320-fold, compared with the parental strain.
(iv) Antibiotic levels in serum. Mean (+ SEM) ceftazidime levels in serum obtained -1 h postdose were 58 + 4.4 ,ug/ml, with no significant differences between animals in either amikacin dose regimen. No ceftazidime was detected in trough serum samples (<0.5 ,ug/ml). Mean (± SEM) amikacin levels in serum were 14 3.4 and 32 ± 2.5 ,ug/ml, respectively, in the lower-and higher-dose regimens in samples obtained 1 h postdose. No amikacin was detected in trough serum specimens (<0.25 ,ug/ml). For pefloxacintreated animals, mean (± SEM) levels in serum obtained -2 h postdose and just before doses were given were 4.9 ± 0.6 and 0.64 ± 0.2 ,ug/ml, respectively. DISCUSSION P. aeruginosa endocarditis involving aortic or mitral valves remains particularly recalcitrant to standard antimicrobial regimens featuring aminoglycoside and P-lactam agents (19, 23, 25) . The newly developed fluoroquinolones (such as pefloxacin) hold much promise for the therapy of such invasive pseudomonal infections for several reasons. (i)
They possess excellent bactericidal activity in vitro against most P. aeruginosa strains (2, 9, 13, 27, 29). (ii) They effectively kill Pseudomonas cells in vitro both at high levels of inocula and during the stationary-growth phase, two features of intravegetation bacteria in endocarditis (12, 27, 30) . (iii) Several quinolones, like pefloxacin, possess extended serum half-lives, with levels achieved above the MIC for most P. aeruginosa strains over the usual dosing intervals (14) .
Several interesting findings were noted in this investigation. Each of the therapy regimens utilized significantly lowered intravegetation pseudomonal counts, compared with untreated controls. However, the in vivo development of both ceftazidime resistance and step-ups in pefloxacin MICs limited the ability of all three therapy regimens to effect complete eradication of intravegetation P. aeruginosa. Pefloxacin therapy was associated with a step-up in MICs for vegetation isolates of four-to eightfold above those of the parental strain, as early as day 4 of treatment. The prevalence of pseudomonal variants with increased pefloxacin MICs was similar at the two sacrifice dates (-30% of sampled vegetations). On retesting by the broth macrodilution technique, the pefloxacin MICs for these variant strains were still within the susceptible range of published breakpoints (<2 -ug/ml [21] ); however, intravegetation isolates possessing MICs of 0.76 to 1.56 ,ug/ml could certainly behave as resistant strains because of the relative bloodvegetation barrier to penetration, which for pefloxacin is -40 to 55% penetration in experimental aortic valve vegetations (A. S. Bayer, D. P. Greenberg, and J. Yih, Chemotherapy [Basel] , in press). There is ample published precedent for infections caused by isolates possessing MICs in the relatively resistant range, behaving as resistant infections when involvement is within foci with penetrability barriers (e.g., relatively resistant pneumococci or viridans streptococci in patients with meningitis or endocarditis, respectively [20, 22] aeruginosa PA-96, no in vivo development of quinolone resistance was detected among intravegetation isolates (3, 5) . However, the ciprofloxacin concentration incorporated into agar plates used for vegetation homogenate subcultures (8 ,ug/ml) was above the MIC susceptibility breakpoint of this agent (2 jig/ml [21] ); it is certainly possible that undetected step-ups in ciprofloxacin MICs, similar to those observed in the current study, were also induced in these latter studies. The increases in ciprofloxacin and ticarcillin MICs and the pleotropic chloramphenicol resistance observed during pefloxacin therapy in the present study are somewhat similar to the nalB, cfxB, and nfxB gene mutations observed in E. coli (17) and the naiB mutation selected in P. aeruginosa (24) . These mutations in E. coli (usually also conferring tetracycline resistance) are associated with decreased amounts of the porin outer membrane protein, OmpF, suggesting that altered drug permeability may be the underlying mechanism for the combined quinolone-chloramphenicol-tetracycline resistances (17) . However, since the porins of E. coli and P. aeruginosa are quite different and because we did not delineate tetracycline resistance in our pseudomonal variants, the genetic locus for the pefloxacin resistance may be different from that defined for E. coli (16) (17) (18) . We are currently in the process of characterizing the mechanism(s) of pefloxacin MIC increases for these variants, focusing on alterations in DNA gyrase and membrane permeability defects.
In vivo development of ceftazidime resistance in this model followed the pattern and mechanisms which we have previously characterized (6) . As in our earlier study, these strains were constitutive overproducers of ,-lactamase. As we have previously observed in this model, amikacin therapy, even at a very high dosage (80 mg/kg per day) did not prevent the emergence of ceftazidime resistance (6) . A major difference in the current study, compared with our earlier experience in treating aortic pseudomonal endocarditis in rabbits, was the lack of in vivo development of amikacin resistance. This finding may relate to the higher daily dosages of amikacin used in this present investigation.
Interestingly in vivo development of quinolone resistance during treatment of serious human infections caused by P. aeruginosa has been most commonly observed in cystic fibrosis-associated pneumonitis (28) . Such infections in humans share one important feature with our animal model of endocarditis, a high in vivo inoculum level; thus, bacterial densities of P. aeruginosa in the lungs of cystic fibrosis patients suffering pulmonary exacerbations reach 106 to 108 CFU/mnl of sputum, similar to pseudomonal densities achieved within aortic vegetations. Since the one-step selection of ciprofloxacin resistance in vitro occurs at a frequency of _10-7 to 10-8 (17, 27) , such high levels of in vivo inocula are probably important in the development of quinolone resistance during therapy.
